Anticoagulation during Renal Replacement Therapy

Area of Science:

• Nephrology
• Critical Care Medicine
• Hematology

Background:

• Renal replacement therapy (RRT) is essential for patients with kidney failure.
• Anticoagulation is necessary to prevent circuit thrombosis during RRT.
• Choosing the appropriate anticoagulation strategy is complex and depends on patient factors and RRT modality.

Purpose of the Study:

• To review and summarize current evidence on anticoagulation for various RRT modalities.
• To provide guidance on selecting optimal anticoagulation strategies in critically ill patients.
• To highlight the risks and benefits of different anticoagulation methods.

Main Methods:

• Literature review of studies on anticoagulation in renal replacement therapy.
• Analysis of guidelines and expert opinions.
• Discussion of anticoagulation protocols for hemodialysis, continuous renal replacement therapy, and peritoneal dialysis.

Main Results:

• Unfractionated heparin remains a common choice but requires careful monitoring.
• Low-molecular-weight heparin offers convenience but has limitations in certain patient populations.
• Regional citrate anticoagulation is effective for continuous renal replacement therapy but requires specialized management.
• Direct oral anticoagulants and direct thrombin inhibitors are emerging options with specific indications.

Conclusions:

• Anticoagulation management during RRT requires individualized approaches.
• Careful consideration of patient-specific factors, RRT modality, and potential bleeding risks is paramount.
• Further research is needed to optimize anticoagulation protocols and explore novel agents in RRT.